• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Sage Therapeutics Inc.

    4/24/25 4:20:03 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAGE alert in real time by email
    DEFA14A 1 sage_-_proxy_2025_defa.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934 (Amendment

    No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

     

    Preliminary Proxy Statement

     

     

     

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

     

    ☐

     

    Definitive Proxy Statement

     

     

     

    ☒

     

    Definitive Additional Materials

     

     

     

    ☐

     

    Soliciting Material under § 240.14a-12

     

    Sage Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

     

    No fee required.

     

     

     

    ☐

     

    Fee paid previously with preliminary materials.

     

     

     

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

     

     


    img102186756_0.jpg

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting To Be Held on June 11, 2025, at 9:00 a.m. Eastern Time Your Vote Counts! SAGE THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 10, 2025 11:59 PM Eastern Time SAGE THERAPEUTICS, INC. 55 CAMBRIDGE PARKWAY CAMBRIDGE, MA 02142 image V72598-P27599 You invested in SAGE THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 11, 2025. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 28, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Logo For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Logo Vote Virtually at the Meeting* June 11, 2025 9:00 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/SAGE2025 *Please check the meeting materials for any special requirements for meeting attendance.


     

    img102186756_1.jpg

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials that are available to you on the Internet. Please follow the instructions on the reverse side to vote these important matters. For a convenient way to view proxy materials, the annual report, VOTE, and obtain directions to attend the meeting virtually, go to: www.virtualshareholdermeeting.com/SAGE2025 Voting Items Board Recommends 1. To elect two directors, James M. Frates and George Golumbeski, Ph.D., each to serve as a Class II director until the 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified, subject to his earlier death, resignation, or removal. Nominees: 01) James M. Frates 02) George Golumbeski, Ph.D. For 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3. To hold a non-binding advisory vote to approve the compensation paid to our named executive officers. For 4. To approve an amendment to our 2014 Employee Stock Purchase Plan, as amended, or the 2014 ESPP, to increase the number of shares of our common stock authorized for issuance under the 2014 ESPP by 500,000 shares. For NOTE: To transact such other business as may properly come before the meeting or any and all adjournments or postponements thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V72599-P27599


    Get the next $SAGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SAGE

    DatePrice TargetRatingAnalyst
    3/11/2025$5.00Underperform
    BofA Securities
    11/21/2024$4.00Underperform → Sector Perform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    10/4/2024$10.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    7/30/2024$16.00 → $10.00Buy → Hold
    TD Cowen
    7/25/2024$18.00 → $12.00Overweight → Neutral
    JP Morgan
    5/29/2024$15.00Neutral
    Robert W. Baird
    5/29/2024$8.00Sell
    Citigroup
    More analyst ratings

    $SAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities resumed coverage on SAGE Therapeutics with a new price target

      BofA Securities resumed coverage of SAGE Therapeutics with a rating of Underperform and set a new price target of $5.00

      3/11/25 7:43:31 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SAGE Therapeutics upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded SAGE Therapeutics from Underperform to Sector Perform and set a new price target of $4.00

      11/21/24 7:42:56 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on SAGE Therapeutics

      Raymond James resumed coverage of SAGE Therapeutics with a rating of Mkt Perform

      10/10/24 8:30:27 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

      For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

      8/8/23 9:34:19 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

      For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

      8/4/23 6:50:31 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

      Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe

      6/16/25 7:00:06 AM ET
      $SAGE
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

      Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth quarter Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 (22% increase from fourth quarter) Cash, cash equivalents, and marketable securities of $424 million as of March 31, 2025; Cash runway expected to support operations to mid-2027 Strategic alternatives review process remains ongoing Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. "We

      4/29/25 4:05:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indic

      4/15/25 6:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    SEC Filings

    See more
    • SEC Form SC TO-C filed by Sage Therapeutics Inc.

      SC TO-C - Sage Therapeutics, Inc. (0001597553) (Subject)

      6/16/25 5:26:56 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC14D9C filed by Sage Therapeutics Inc.

      SC14D9C - Sage Therapeutics, Inc. (0001597553) (Subject)

      6/16/25 5:20:11 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC TO-C filed by Sage Therapeutics Inc.

      SC TO-C - Sage Therapeutics, Inc. (0001597553) (Subject)

      6/16/25 11:40:45 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Germano Geno J

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      6/13/25 4:14:14 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Golumbeski George

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      6/13/25 4:14:04 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Frates James M

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      6/13/25 4:13:57 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Leadership Updates

    Live Leadership Updates

    See more
    • Sage Therapeutics Announces R&D Leadership Transition

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

      3/4/25 4:15:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Appoints Jessica Federer to Board of Directors

      Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005117/en/Jessica Federer (Photo: Business Wire) "We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Jessica's innate curiosit

      3/16/23 6:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer

      Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage's current and emerging product pipeline through all stages of development. "We are thrilled to have Dr. Gault join Sage to lead the development and delivery of our pipeline of potential new medicines and be a partner in our mission to improve the lives of people affected by brain health disorders," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Dr. Gault's vision, experience and deep commitment to this field of med

      11/1/22 7:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

      SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

      11/14/24 6:14:58 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

      SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

      11/12/24 4:56:16 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

      SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

      11/12/24 10:34:18 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Financials

    Live finance-specific insights

    See more
    • Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

      Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe

      6/16/25 7:00:06 AM ET
      $SAGE
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

      Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth quarter Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 (22% increase from fourth quarter) Cash, cash equivalents, and marketable securities of $424 million as of March 31, 2025; Cash runway expected to support operations to mid-2027 Strategic alternatives review process remains ongoing Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. "We

      4/29/25 4:05:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indic

      4/15/25 6:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care